The landscape of preclinical drug discovery is undergoing a profound metamorphosis. For decades, the pathology laboratory was a terminal destination for biological samples: a slide was prepared, examined by a pathologist, and subsequently consigned to long-term storage, its data potential largely exhausted. Today, a paradigm shift is underway, driven by the rapid evolution of digital pathology and the urgent, regulatory-backed mandate to reduce reliance on animal models.
By leveraging digitized slides and long-archived tissue samples, researchers are now mining existing data to extract novel insights, effectively "recycling" previous experiments to spare future ones. This transition, championed by leaders like Dr. Aleksandra Zuraw of Charles River Laboratories, is turning the pathology slide from a simple diagnostic snapshot into a living, high-dimensional data asset.
The Evolution of the Digital Slide
The catalyst for this shift was the COVID-19 pandemic, which forced a global decentralization of pathology workflows. As physical access to laboratories became restricted, the necessity of remote digital sign-outs transformed digital pathology from a niche, high-cost luxury into a fundamental operational requirement.
"Before, the pathology endpoint was just a report," explains Dr. Aleksandra Zuraw, DVM, PhD, a veterinary pathologist at Charles River Laboratories. "Now, you have the digitized slide, which is pixels."
This digitization has unlocked a new era of computational analysis. By pairing high-resolution images with original pathology reports and molecular data, researchers are training machine learning models to identify subtle patterns—molecular markers of disease or drug toxicity—that remain invisible to the human eye. The slide is no longer a one-way street; it is a repository of biological information waiting for the right algorithm to unlock it.
Chronology of a Paradigm Shift: From Regulatory Mandates to Routine Practice
The transition toward New Approach Methodologies (NAMs) in drug discovery has been accelerated by both technological capability and legislative pressure.
- 2022 (The Legislative Catalyst): The enactment of the FDA Modernization Act 2.0 marked a historic pivot, formally allowing for non-animal methods to support Investigational New Drug (IND) applications. This provided the legal framework necessary for industry stakeholders to invest heavily in alternatives.
- April 2024: Charles River Laboratories launched its "Alternative Methods Advancement Project," a strategic initiative aimed at integrating digital workflows and data-driven alternatives into the standard toxicology pipeline.
- April 2025: The FDA published a comprehensive roadmap for reducing animal testing in preclinical safety studies. The document laid out a multi-year strategy, beginning with monoclonal antibodies and expanding to broader biologics and chemical entities, with the ultimate goal of making animal testing the exception rather than the rule.
- 2025-2026 (Methodological Standardization): The OECD provided updated guidance on sample collection for "omics" analysis, establishing rigorous standards for how archived tissue can be leveraged to support gene expression and protein studies, ensuring that quality and consistency are maintained across retrospective analyses.
- September 2026: The FDA issued further updates to regulations, reinforcing the push for innovative alternatives and providing clearer expectations for how these data should be presented to regulators.
The Power of Virtual Control Groups and Archived Tissue
One of the most immediate impacts of this digitization is the reduction of animal usage through "virtual control groups." In traditional toxicology, a significant portion of animal subjects are designated as concurrent controls to establish a baseline for health.
"Control animals are always a big fraction of every study," Dr. Zuraw notes. By curating extensive databases of historical, matched control data, researchers can now perform comparative analyses against virtual cohorts, significantly reducing the number of animals required for each new study. This is not merely a reduction in numbers; it is a refinement of efficiency that relies on the mathematical rigor of historical data comparability.
Furthermore, the industry is rediscovering the value of Formalin-Fixed, Paraffin-Embedded (FFPE) blocks. These archives hold a wealth of latent data. In the past, if a post-study question regarding drug mechanism arose, the standard procedure often involved initiating a new animal study to gather fresh tissue. Today, that is increasingly unnecessary. Researchers can now return to the archived blocks to perform molecular assays—such as transcriptomics or proteomics—that provide the necessary answers within the context of the original study.
Supporting Data and Technological Advancements
The efficacy of this new approach rests on several key technological pillars, most notably the rise of "virtual staining."

Virtual staining represents the next leap in computational biology. Rather than relying on traditional chemical dyes—which can be inconsistent and labor-intensive—scanners capture unstained tissue, and software algorithms generate the appearance of a stain. As a 2026 review in the field highlights, this technology is moving rapidly from laboratory demonstration to standardized clinical and preclinical use.
By "skipping the glass" and working entirely in the digital domain, laboratories can minimize reagent waste, reduce processing time, and maintain a consistent data output that is perfectly suited for AI-driven pattern recognition. This creates a "snowball effect": as more labs digitize their workflows to take advantage of these tools, the volume of high-quality data available for training models grows, making the tools themselves more accurate and more valuable.
Official Responses and Regulatory Implications
The FDA’s current stance is clear: the agency is actively moving to dismantle the bureaucratic and scientific hurdles that have long favored traditional animal testing. By positioning itself as a proponent of innovation, the agency is encouraging pharmaceutical companies to adopt NAMs as a standard of quality.
However, Dr. Zuraw emphasizes that regulatory approval is only half the battle. "You still need enough early adopters to generate precedent," she says. The industry is currently in a phase of "proof-of-principle," where companies must demonstrate that these virtual methods provide data that is not only comparable to but often more granular than traditional methods. As these early adopters troubleshoot these workflows and establish best practices, the rest of the industry will be able to follow, effectively "building on their work without reinventing the wheel."
Future Implications: The "New Normal" in Preclinical Research
The shift toward mining archived tissue and implementing virtual controls is more than a cost-saving measure; it is a transformation of the scientific process.
1. Enhanced Data Integrity
By using digital archives, researchers can re-examine studies years after completion with modern analytical tools. This allows for the longitudinal tracking of drug safety data that was previously impossible to synthesize.
2. Ethical and Financial Efficiency
Reducing animal usage aligns with the industry’s broader ESG (Environmental, Social, and Governance) goals. By minimizing the reliance on animal models, companies can reduce the time-to-market for life-saving therapeutics while simultaneously adhering to the highest ethical standards of laboratory research.
3. A New Generation of Pathologists
The role of the pathologist is evolving. The modern pathologist must be as comfortable with data science and software interfaces as they are with the traditional microscope. This interdisciplinary approach is essential for interpreting the results of complex digital models and ensuring that the data being extracted from archived tissue is biologically sound.
Conclusion: The Path Forward
The "next act" for digital pathology is a transition from a reactive, slide-viewing tool to a proactive, data-mining powerhouse. By integrating historical archives with AI-driven insights, the preclinical research community is building a framework where every animal study contributes to a larger, cumulative knowledge base.
As we look toward a future where animal models become the exception, the groundwork being laid today by organizations like Charles River Laboratories and regulators at the FDA serves as a testament to the power of technological integration. We are entering an era where the most valuable scientific assets are not just the animals themselves, but the data they leave behind—a legacy of knowledge that will continue to inform, refine, and accelerate drug discovery for years to come.
